Get the Stockscreener App
0.1501
100.00%
0.0772
Bluejay Diagnostics Inc stock is traded at $0.1501, with a volume of 741.94M.
It is up +100.00% in the last 24 hours and up +8.64% over the past month.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
See More
Previous Close:
$0.0729
Open:
$0.0741
24h Volume:
741.94M
Relative Volume:
57.23
Market Cap:
$2.87M
Revenue:
-
Net Income/Loss:
$-9.40M
P/E Ratio:
-0.0142
EPS:
-10.55
Net Cash Flow:
$-8.52M
1W Performance:
+47.57%
1M Performance:
+8.64%
6M Performance:
-96.67%
1Y Performance:
-99.50%
1-Day Range:
$0.0741
$0.249
1-Week Range:
$0.0728
$0.249
52-Week Range:
$0.0728
$31.28
Bluejay Diagnostics Inc Stock (BJDX) Company Profile
Name
Bluejay Diagnostics Inc
Sector
Industry
Phone
(978) 631-0152
Address
360 MASSACHUSETTS AVENUE, SUITE 203, ACTON
Bluejay Diagnostics Inc Stock (BJDX) Latest News
U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn
Does Bluejay Diagnostics Inc (NASDAQ: BJDX) Still Look Hot This Week? - Stocks Register
BJDX stock touches 52-week low at $0.08 amid sharp annual decline - Investing.com Australia
Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America - Marketscreener.com
Buejay Diagnostics, Inc Announces Results from the Primary Analysis of SYMON-I - Marketscreener.com
Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Grows By 300.8% - Defense World
Bluejay Diagnostics shareholders approve reverse stock split - Investing.com India
Bluejay Diagnostics shareholders approve reverse stock split By Investing.com - Investing.com UK
Bluejay Diagnostics Inc’s (BJDX) -5.05% Retreat Justifies A Second Look - Stocks Register
Bluejay Diagnostics adjusts stockholder meeting quorum By Investing.com - Investing.com South Africa
Bluejay Diagnostics adjusts stockholder meeting quorum - Investing.com India
Bluejay Diagnostics stock hits 52-week low at $0.1 - Investing.com
Bluejay Diagnostics stock hits 52-week low at $0.1 By Investing.com - Investing.com UK
The Potential Rise in the Price of Bluejay Diagnostics Inc (BJDX) following insiders activity - Knox Daily
An analyst sees good growth prospects for Bluejay Diagnostics Inc (BJDX) - SETE News
Bluejay Diagnostics Inc (BJDX) Stock: A Year of Market Fluctuations - The InvestChronicle
BJDX’s current quarter earnings: What analysts forecast? - US Post News
Market Resilience: Bluejay Diagnostics Inc (BJDX) Finishes Weak at 0.12, Down -1.78 - The Dwinnex
Check out these key findings about Bluejay Diagnostics Inc (BJDX) - SETE News
Bluejay Diagnostics Inc [BJDX] Insider Activity: An Update for Investors - Knox Daily
Bluejay Diagnostics Inc: Analyzing BJDX Stock Trends - The InvestChronicle
BJDX stock touches 52-week low at $0.12 amid sharp annual decline - Investing.com India
Is Bluejay Diagnostics Inc (BJDX) a opportunity to investors? - US Post News
Market cap of Bluejay Diagnostics Inc [BJDX] reaches 2.21M – now what? - The DBT News
There is no doubt that Bluejay Diagnostics Inc (BJDX) ticks all the boxes. - SETE News
Behind Bluejay Diagnostics Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Market Recap Check: Bluejay Diagnostics Inc (BJDX)’s Positive Finish at 0.14, Up/Down 0.86 - The Dwinnex
Should investors be concerned about Bluejay Diagnostics Inc (BJDX)? - US Post News
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Down 9.4% in September - Defense World
Bluejay Diagnostics stock hits 52-week low at $0.13 By Investing.com - Investing.com South Africa
Bluejay Diagnostics stock hits 52-week low at $0.13 - Investing.com
BJDX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
A Look at Bluejay Diagnostics Inc (BJDX) Shares in the Recent Past Indicates Growth - SETE News
Blue Jays' Zach Pop: Optioned to minors - CBS Sports
Trading Day Triumph: Biodesix Inc (BDSX) Ends at 1.59, a -11.67 Surge/Plunge - The Dwinnex
Are Bluejay Diagnostics Inc (BJDX) shares a good deal now? - US Post News
IT Stock Hits 5% Upper Circuit On Expanding Into Healthcare Industry - Goodreturns
Ratio Examination: Bluejay Diagnostics Inc (BJDX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Blue Cloud Softech Solutions shares hit 5 percent upper circuitCheck details - India.com
Bluejay Diagnostics (NASDAQ:BJDX) versus Plus Therapeutics (NASDAQ:PSTV) Head-To-Head Review - Defense World
Bluetongue vaccine: Virbac announces arrival of Syvazul BTV3 - vet times
155675 (BLD.TO) to Post Q3 2024 Earnings of ($0.20) Per Share, Cormark Forecasts (TSE:BLD) - Defense World
Rs 3546 crore order book & 800 per cent multibagger returns: Civil construction company bags new order worth Rs 221 crore from SSS Realty & Co - Dalal Street Investment Journal
Taking on analysts’ expectations and winning: Bluejay Diagnostics Inc (BJDX) - SETE News
New measures introduced to mitigate spread of BTV - Agriland.co.uk
BJDX underperforms with a -0.79 decrease in share price - US Post News
Deeper Dive: Understanding Bluejay Diagnostics Inc (BJDX) Through its Various Ratios - The Dwinnex
What is Bluejay Diagnostics Inc (BJDX) Stock Return on Shareholders’ Capital? - SETE News
In the Green: Bluejay Diagnostics Inc (BJDX) Closes at 0.15, Up/Down -2.16 from Previous Day - The Dwinnex
Is Bluejay Diagnostics Inc (BJDX) worth investing in despite its undervalued state? - US Post News
BJDX stock plunges to 52-week low of $0.15 amid steep decline - Investing.com Australia
Bluejay Diagnostics Inc Stock (BJDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):